Risk of hypotension with concomitant use of calcium-channel blockers and macrolide antibiotics

American Journal of Health-System Pharmacy

Volumn 69, Issue 12, 2012, Pages 1038-1043

  Henneman, Amy ^a   Thornby, Krisy Ann ^a  

^a PALM BEACH ATLANTIC UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; AZITHROMYCIN; BUDESONIDE; CALCIUM CARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLARITHROMYCIN; COLECALCIFEROL; CYTOCHROME P450 3A4; DIGOXIN; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DOXAZOSIN; ERYTHROMYCIN; FELODIPINE; FLUINDOSTATIN; FUROSEMIDE; GLIBENCLAMIDE; MACROLIDE; METFORMIN; NIFEDIPINE; PROPRANOLOL; SALBUTAMOL; VERAPAMIL;

AGING; BEDTIME DOSAGE; BRADYCARDIA; CARDIOVASCULAR EFFECT; COMORBIDITY; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART LEFT BUNDLE BRANCH BLOCK; HUMAN; HYPERTENSION; HYPOTENSION; LETHARGY; NAUSEA; PALLOR; PARANASAL SINUS DISEASE; PNEUMONIA; POLYPHARMACY; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATORY TRACT INFECTION; REVIEW; RISK ASSESSMENT; SHOCK; SYNCOPE; TREATMENT INDICATION; WEAKNESS;

EID: 84862872434     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110486     Document Type: Review

References (20)

1. Keenan NL, Rosendorf KA. Prevalence of hypertension and controlled hypertension - United States, 2005-2008. MMWR Surveill Summ. 2011; 60(suppl 1):94-7.
2. Centers for Disease Control and Prevention. Vital signs: prevalence, treatment, and control of hypertension - United States, 1999-2002 and 2005-2008. MMWR. 2011; 60:103-8.
3. IMS Health Institute for Informatics. Top therapeutic classes by prescriptions. In: The use of medicines in the United States: review of 2010. www.imshealth.com/imshealth/Global/Content/IMS%20Institute/Documents/ IHII-UseOfMed-report%20.pdf (accessed 2012 Mar 8).
4. Fisher AA, McLean AJ, Davis MW et al. A multicenter, case-control study of the effects of antihypertensive therapy on orthostatic hypotension, postprandial hypotension, and falls in octo- and nonagenarians in residential care facilities. Curr Ther Res. 2003; 64:206-14. (Pubitemid 36532622)
5. Fotherby MD, Potter JF. Orthostatic hypotension and anti-hypertensive therapy in the elderly. Postgrad Med J. 1994; 70:878-81.
6. Mader SL, Josephson KR, Rubenstein LZ. Low prevalence of postural hypotension among community-dwelling elderly. JAMA. 1987; 258:1511-4. (Pubitemid 17138100)
7. Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. www.fda.gov/drugs/ developmentapprovalprocess/developmentresources/druginteractionslabeling/ ucm093664.htm (accessed 2012 Mar 7).
8. Lexi-Drugs Online. Lexi-Comp Online website. http://online.lexi.com/ crlsql/servlet/crlonline (accessed 2011 Nov 9).
9. DRUGDEX System [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare Inc.). Updated periodically (accessed 2011 Nov 9).
10. Wright AJ, Gomes T, Mamdani MM et al. The risk of hypotension following coprescription of macrolide antibiotics and calcium-channel blockers. CMAJ. 2011; 183:303-7
11. Kaeser YA, Brunner F, Drewe J et al. Severe hypotension and bradycardia associated with verapamil and clarithromycin. Am J Health-Syst Pharm. 1998; 55:2417-8. Letter. (Pubitemid 28538076)
12. Goldschmidt N, Azaz-Livshits T, Gotsman I et al. Compound cardiac toxicity of oral erythromycin and verapamil. Ann Pharmacother. 2001; 35:1396-9. (Pubitemid 33042075)
13. Steenbergen JA, Stauffer VL. Potential macrolide interaction with verapamil. Ann Pharmacother. 1998; 32:387-8. Letter.
14. Gerónimo-Pardo M, Cuartero-del-Pozo AB, Jimenez-Vizuete JM et al. Clarithromycin- nifedipine interaction as possible cause of vasodilatory shock. Ann Pharmacother. 2005; 39:538-42. (Pubitemid 40270922)
15. Liedholm H, Nordin G. Erythromycinfelodipine interaction. DICP. 1991; 25:1007-8. Letter.
16. Bailey DG, Bend JR, Arnold JM et al. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther. 1996; 60:25-33. (Pubitemid 26279217)
17. Ray WA, Murray KT, Meredith S et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004; 351:1089-96.
18. Biaxin (clarithromycin) package insert. North Chicago, IL: Abbott Pharmaceuticals Ltd.; 2011.
19. Erythromycin delayed-release capsules package insert. North Chicago, IL: Abbott Pharmaceuticals Ltd.; 2009.
20. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40:373-83. (Pubitemid 17055592)